Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$37.27 - $50.24 $95,038 - $128,112
-2,550 Reduced 53.39%
2,226 $85,000
Q4 2022

Sep 21, 2023

BUY
$33.44 - $54.8 $159,709 - $261,724
4,776 New
4,776 $261,000
Q4 2022

Feb 14, 2023

BUY
$33.44 - $54.8 $159,709 - $261,724
4,776 New
4,776 $261,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.3B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Jefferies Financial Group Inc. Portfolio

Follow Jefferies Financial Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Financial Group Inc. with notifications on news.